IL6 and neoplasm: Recent studies show that IL-6 ligand and receptor targeted therapies can inhibit the survival of cancer stem cells, delay tumor initiation, prevent tumor recurrence, and enhance the anti-tumor effect of conventionalchemotherapy [8, 54, 65].